About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
 Menu
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

logo-iconLog in with Doximity
or
Forgot Password

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

logo-iconLog in with Doximity
or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Specialties

Choose 1 or more specialties that you are interested in:

Subspecialties

You can specify a subspecialty for areas you selected (if available):

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
Previous Next skip
Our Science

    • Marizomib (Proteasome Inhibitor)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    Proposed Mechanism of Action

    Marizomib is a proteasome inhibitor derived from a novel marine-obligate actinomycete that belongs to the β-lactone-γ-lactam superfamily of proteasome inhibitors.1 In in vitro experiments, marizomib has demonstrated irreversible binding to and inhibition of all 3 proteolytic subunits of the human proteasome complex, resulting in inhibition of proteasome activity.2,3

    Celgene acquired this asset from Triphase in 2016. Triphase continues to support marizomib’s development by remaining involved with the ongoing clinical trials.

    Marizomib by Disease State

    Marizomib in Solid Tumors

    Phase 3
    Newly diagnosed glioblastoma

    View Trials Investigating Marizomib in Solid Tumors
    View Rationale for Clinical Development

    Rationale for Clinical Development

    In vitro experiments have revealed that marizomib inhibited proliferation and invasion and induced apoptosis in glioma cells.4 In addition, studies in rats demonstrated distribution of marizomib into the brain, and studies in monkeys demonstrated inhibition of chymotrypsin-like proteasome activity in brain tissues.4

    View Related Pathways

    Proteasome Pathway

    References

    1. Feling RH, et al. Angew Chem Int Ed Engl. 2003;42:355-357. PMID: 12548698
    2. Groll M, et al. J Am Chem Soc. 2006;128:5136-5141. PMID: 16608349
    3. Chao T-H, et al. 100th Annual AACR Meeting [abstract 4539].
    4. Di K, et al. Neuro Oncol. 2016;18:840-848. PMID: 26681765